Therapy (HCV)

Decision Analysis for IFN Therapy Flawed

Published in Hepatitis Weekly, March 24th, 1997

Accurate decision analysis to assess chronic hepatitis C treatment is badly needed but not likely as long as there are gaps in the current understanding of the natural progression of the disease.

Randomized, double-blind, controlled clinical trials are the gold standard for evaluating the value of medical therapies, but such trials sometimes can be generalized only to a limited extent, and where event rates are low or the events occur over an extended time period, these trials require substantial numbers of patients or long follow-up times.

Currently, there are compelling arguments for and against the treatment of patients with mild chronic hepatitis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1997-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry